🎙 Tech and Drugs – Season 02, Episode 02
From Tennis Courts to Molecular Design: Tim Hoctor on Data, Discovery, and the Future of Pharma

Last December in Berlin, I had the privilege of sitting down with my friend and longtime mentor Tim Hoctor, one of the true legends at the intersection of technology and life sciences.

Tim’s career defies categories.

He started as a professional tennis player in California. From there, he stepped into early Silicon Valley startups, then into Molecular Design Limited, the birthplace of computerized chemical registration and what many still call the “MDL Mafia.” Later, he became a senior leader at Elsevier, helping shape how scientific data, literature, and databases connect in the digital era.

This conversation is part industry history lesson, part strategic deep dive, and part personal reflection.

What we cover:

✔️ Tim’s unconventional journey from tennis pro to engineer to life sciences data executive
✔️ How MDL pioneered digital molecular representation and why it became foundational to modern pharma
✔️ Why linking structured databases to scientific literature was visionary in the 1990s and still unfinished business today
✔️ The persistent data silos in pharma and why culture, more than technology, is often the bottleneck
✔️ Why 6 billion dollar drug development costs are a systems problem, not just a science problem
✔️ The real role of regulators in AI adoption and how agencies are asking industry to help define the future
✔️ What COVID changed forever in automation, digital adoption, and supply chain resilience
✔️ How tools like ChatGPT are reshaping behavior across pharma teams
✔️ Why pharma still hasn’t had its “SpaceX moment” and what it would take to truly disrupt the model
✔️ The vision of garage biotech powered by autonomous labs, shared data, and AI driven discovery

Tim speaks with rare clarity about what holds our industry back, what gives him hope, and why better data sharing may ultimately matter more than the next algorithm.

If you care about the evolution of pharma R&D, the cultural barriers to AI adoption, and what it will take to move from incremental efficiency to true system level change, this episode is for you.

I hope you enjoy this conversation as much as I did.